Brief Report

Minimizing Glucose Excursions (GEM) With Continuous Glucose Monitoring in Type 2 Diabetes: A Randomized Clinical Trial

Daniel J. Cox,1 Tom Banton,1 Matthew Moncrief,1 Mark Conaway,2 Anne Diamond,1 and Anthony L. McCall3

1University of Virginia School of Medicine, Center for Behavioral Medicine Research, Charlottesville, Virginia 22908; 2University of Virginia School of Medicine, Public Health Sciences, Charlottesville, VA 22908; and 3University of Virginia School of Medicine, Endocrinology and Metabolism, Charlottesville, VA 22908

ORCID number: 0000-0002-0910-5306 (D. J. Cox).

Abbreviations: ASA24, automated self-administered 24-hour dietary recall; AUC, area under the curve; BG, blood glucose; CDC, centers for disease control; CGM, continuous glucose monitoring; GEM, glycemic excursion minimization; GEMCGM, glycemic excursion minimization plus real-time continuous glucose monitoring; HbA1c, glycated hemoglobin; MES, medication effect scale; PHQ9, Patient Health Questionnaire-9; RC, routine care; T2D, type 2 diabetes; TTE, total treatment effect; WHO, World Health Organization.

Received: 2 April 2020; Accepted: 17 August 2020; First Published Online: 18 August 2020; Corrected and Typeset: 14 October 2020.

Abstract

This study aimed to compare conventional medication management of type 2 diabetes (T2D) to medication management in conjunction with a lifestyle intervention using continuous glucose monitoring to minimize glucose excursions. Thirty adults (63% female; mean age, 53.3 years) who were diagnosed with T2D for less than 11 years (mean, 5.6 years), had glycated Hb (HbA1c) ≥ 7.0% (51 mmol/mol) (mean 8.8%, [73 mmol/mol]), and were not using insulin, were randomly assigned in a 1:2 ratio to routine care (RC) or 4 group sessions of glycemic excursion minimization plus real-time CGM (GEMCGM). Assessments at baseline and 5 months included a physical exam, metabolic and lipid panels, a review of diabetes medications, and psychological questionnaires. For the week following assessments, participants wore a blinded activity monitor and completed 3 days of 24-hour dietary recall. A subgroup also wore a blinded CGM. GEMCGM participants significantly improved HbA1c (from 8.9% to 7.6% [74-60 mmol/mol] compared with 8.8% to 8.7% [73-72 mmol/mol]) for RC (P = .03). Additionally, GEMCGM reduced the need for diabetes medication (P = .01), reduced carbohydrate consumption (P = .009), and improved diabetes knowledge (P = .001), quality of life (P = .01) and diabetes distress (P = .02), and trended to more empowerment (P = .05) without increasing dietary fat, lipids, or hypoglycemia. Confirming our prior research, GEMCGM appears to be a safe, effective lifestyle intervention option for adults with suboptimally controlled T2D who do not take insulin.

Key Words: type 2 diabetes mellitus, glycemic load, exercise, physical activities, continuous glucose monitoring, postprandial blood glucose
Pharmacological and lifestyle interventions are both important components of managing type 2 diabetes (T2D), but compared to the wide variety of pharmaceutical interventions with several different mechanisms of action, there are few lifestyle intervention options that are offered and they are often perceived to be difficult and complicated. The American Diabetes Association recommends 150 minutes per week of moderate physical activity plus 7% weight loss through caloric restriction [1]. Weight loss is not a viable option for patients who do not need or want to lose weight, are unable to lose weight, or cannot maintain weight loss. Consequently, lifestyle interventions with a different approach are needed.

More recently, the American Diabetes Association stated: “Reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia and may be applied in a variety of eating patterns” [2].

Previously, we reported on a new lifestyle intervention for T2D that, instead of focusing on reducing weight, shifts the focus to reducing postprandial glucose [3], which is a primary contributor to glycated hemoglobin (HbA$_1c$) [4]. This program is called glycemic excursion minimization (GEM), which reflects its goal of minimizing postnutrient (meals, snacks, drinks) blood glucose (BG) excursions, or area under the curve (AUC). This initial study had 5 sessions of face-to-face GEM instruction and employed systematic BG monitoring [5]; it measured BG both before and 2 hours after meals and before and 30 minutes following exercise. BG feedback was used to educate participants regarding how different amounts and kinds of food and exercise affected their BG and to motivate them to repeat those choices that led to desirable BG levels.

Participants were also encouraged to use BG feedback to activate them to make choices consistent with their current BG level and personal BG targets. For example, if participants discovered their BG was higher than desired before a meal, they could choose to postpone eating or take a brisk walk to lower their BG. However, the use of systematic BG was problematic because some people did not like pricking their finger, seeing blood, always having BG monitoring supplies available before and after eating and exercising, or trying to remember to monitor BG at specific times.

Continuous glucose monitoring (CGM) is an attractive alternative to systematic BG monitoring. CGM reduces the frequency of finger pricks, the need to remember equipment and when to take BG measurements, and it provides a more comprehensive BG record than systematic BG monitoring. These advantages could enhance the benefits of GEM [6]. Therefore, we hypothesized that relative to routine care (RC), GEM with CGM feedback (GEM$^{CGM}$) would 1) significantly improve the primary outcome variables of HbA$_1c$ and need for diabetes medication; 2) achieve these results through the mechanisms of increasing knowledge concerning food and activity choices, reducing consumption of carbohydrates, increasing routine physical activity, and diminishing BG excursions as reflected in CGM profiles; 3) have the secondary benefits of improving quality of life, empowerment, and diabetes distress; and 4) not have side effects like episodes of hypoglycemia [7] or increased compensatory fat consumption.

1. **Materials and Methods**

**A. Participants**

Thirty adults with T2D were recruited through radio and print advertisements and the University of Virginia Hospital patient registry between July 2018 and August 2019. GEM$^{CGM}$ training was conducted between December 2018 and September 2019, and 3-month follow-up assessments were performed between April 2019 and January 2020. Participants were between ages 30 and 80 years, had T2D for less than 11 years, had an HbA$_1c$ greater than or equal to 7.0% (53 mmol/mol), were not on insulin or nondiabetic medications that could affect BG control (eg, prednisone), were able to walk for 30 minutes, and were interested in CGM. They were randomly assigned to RC or GEM$^{CGM}$. Incentives to participate were free blood tests, blood glucose meters and supplies (Bayer Contour), activity monitors (Fitbit Charge 2), $100 on completion of postassessment, and CGM supplies if assigned to GEM$^{CGM}$. The demographics of this sample appear in Table 1. The 2 groups did not significantly differ on any demographic variables.

**B. Procedures**

After being thoroughly informed, participants signed a University of Virginia institutional review board–approved

---

**Table 1.** Demographic characteristics of routine care (RC) and glycemic excursion minimization plus real-time continuous glucose monitoring (GEM$^{CGM}$) groups

|                | HbA$_1c$, % | Duration of T2D, y | BMI, kg/m$^2$ | Female, % | White, % | Black, % | Age, y | Education, y |
|----------------|-------------|-------------------|---------------|-----------|---------|---------|-------|-------------|
| RC             | 8.8 ± 1.2   | 5.9 ± 2.5         | 35.6 ± 8.4    | 80        | 60      | 30      | 50.8 ± 14.2 | 16.1 ± 3.5  |
| GEM$^{CGM}$    | 8.9 ± 1.8   | 5.4 ± 2.7         | 33.5 ± 3.9    | 50        | 85      | 10      | 54.6 ± 12.2 | 14.8 ± 2.9  |

**Abbreviations:** BMI, body mass index; HbA$_1c$, glycated hemoglobin; T2D, type 2 diabetes.
consent form. Next, they participated in a baseline assessment that included a brief physical, blood tests for HbA1c and lipids, a review of their current medications, and psychological questionnaires to assess attitudes toward glucose monitoring [8], quality of life [9], diabetes empowerment [10], diabetes distress [11], and depressive symptoms [12]. Using the Medication Effect Scale (MES) [13], the dose and type of each diabetes medicine in a participant’s medication regimen was converted to a common denominator—that medication’s average HbA1c-lowering potential. These potentials were then summed over the diabetes medications the individual was taking to estimate the potential HbA1c-lowering effect of a participant’s medication regimen. The following week participants wore a blinded activity monitor (Fitbit Charge 2), and were interviewed over the telephone on 2 work days and 1 weekend day to complete the automated self-administered 24-hour dietary recall dietary recall [14]. Ten RC and 12 GEMCGM participants also wore a blinded CGM (Dexcom Platinum G4). This assessment was repeated a second time 5 months later—3 months after the conclusion of GEMCGM.

Following the baseline assessment, participants were randomly assigned, by a flip of a coin in blocks of 3 by the data manager, who was unfamiliar with the individual, to either GEMCGM or RC in a 2:1 ratio; if “heads” came up during the first 2 participants, they were assigned to RC, and if “heads” did not come up then the third person was assigned to RC. All participants continued their usual care in consultation with their treating physician, who adjusted medication as clinically indicated throughout the 5-month study. One RC patient dropped out before postassessment to pursue bariatric surgery.

The 2-month GEMCGM intervention period involved meeting in groups of 8 to 10 for 90 minutes on 4 occasions, with 1 week between sessions 1 and 2 and 3 weeks between sessions 2 and 3 and 3 and 4 (Fig. 1). At each session, participants were given a 7-day Dexcom G5 sensor, and 1 month after session 4, a fifth sensor was given. This timing was intended to diminish reliance on CGM and group support and to encourage autonomy following the conclusion of the intervention. Follow-up assessment occurred three months after session 4.

With the assistance of an instructor’s manual, a diabetes nurse educator (A.D.) led group sessions. GEMCGM participants were given a 98-page manual and a diary that focused on the following:

- Session 1, Educating participants how their routine choices of types and amounts of food and physical activity affected their BG with the assistance of CGM feedback.
- Session 2, Reducing and eventually eliminating common high net carbohydrate foods with replacement and substitution, the results of which are reflected in CGM feedback. Participants were also instructed on the possibility and management of hypoglycemia.
- Session 3, Increasing mild and moderate physical activity, especially postprandial, both to increase direct glucose utilization and enhance insulin sensitivity. Again, CGM feedback was used to demonstrate the personal consequences/benefits of such choices.

| Day | Study Segment | Study Event |
|-----|---------------|-------------|
| 1   | Pre-assessment | Blood tests, vital signs, psychologicals |
| 2-7 | Pre-assessment | Collect blind CGM, activity monitor, ASA24 |
| 8   | Treatment     | Session 1   |
| 15  | Treatment     | Session 2   |
| 36  | Treatment     | Session 3   |
| 57  | Treatment     | Session 4   |
| 182 | 3-month follow-up | Blood tests, vital signs, psychologicals |
| 183-189 | 3-month follow-up | Collect blind CGM, activity monitor, ASA24 |

Figure 1. Timeline of study events. Glycemic excursion minimization plus real-time continuous glucose monitoring (GEMCGM) participants received one 7-day Dexcom G5 sensor at each of the 4 training sessions.
• Session 4, Continuing and enhancing optimal food and activity choices over a lifetime and managing relapses.

At the beginning of each session, participants were asked to report the number of hypoglycemic experiences they had since the previous session, regarding level 1 (low enough for treatment), level 2 (sufficiently low to indicate serious, clinically important hypoglycemia), and level 3 (associated with severe cognitive impairment requiring external assistance for recovery) hypoglycemic events [7]. GEM CGM participants were given 5 G5 sensors, 1 to insert at each session and 1 to be inserted 8 weeks before the 3-month follow-up assessment.

Three-month follow-up assessments were conducted between February 2019 and December 2019. Pre and post change scores for RC and GEM CGM were compared in analyses of covariance, with baseline measures serving as the covariant. SPSS version 25 was used to perform the analyses.

2. Results

A. Primary Outcome Variables

Fig. 2 displays the mean and SD of pre and post change in HbA1c, MES, and the total treatment effect (TTE), which combines HbA1c and MES as an HbA1c-equivalent impact of the intervention. GEM CGM significantly reduced HbA1c 1.11% more than RC and significantly reduced MES 0.83 more than RC. The combination of these, the TTE, separated RC from GEM CGM by an HbA1c equivalent of 1.94% (P < .001, see Fig. 2 and Table 2).

Table 2 displays the pre and post means, SDs, F tests, and probabilities of the primary outcomes, mechanisms, secondary, and side effect variables.

B. Mechanism Variables

As hypothesized, GEM CGM did produce a significant increase in knowledge and led to a reduction in carbohydrate ingestion relative to RC. GEM CGM did not significantly differ from RC in regards to increased physical activity or decreased glucose excursions (as quantified by AUC or time in range). However, change in the following variables did correlate with change in HbA1c: Fitbit calories burned (r = −0.40, P = .01) and minutes of daily moderate to vigorous activity (r = −0.37, P = .04); CGM AUC (r = 0.61, P = .009), and CGM time in range (r = −0.62, P = .006). Additionally, responsiveness to GEM CGM was not limited by depressive symptoms because baseline Patient Health Questionnaire-9 (PHQ9) did not correlate with change in HbA1c (r = −0.13, P = .50). This negative outcome was further confirmed when comparing participants with and without significantly elevated baseline PHQ9 scores (> 9) in regard to change in HbA1c, MES, or TTE (P = .51, .31, and .82, respectively).

C. Secondary Outcome Variables

As hypothesized, GEM CGM significantly improved psychological function relative to RC, including World Health Organization (WHO)-Quality of Life (Psychological subscale), Diabetes Empowerment, Diabetes Distress Scale (Emotional and Regimen subscales), and the Glucose Monitor Satisfaction Survey. It did not significantly improve WHO-Quality of Life (Physiological subscale).

D. Side Effects

GEM CGM did not lead to an increase in caloric, fat, or protein consumption nor a worsening in lipids relative to RC. Self-report experiences with hypoglycemia were not collected among RC participants. GEM CGM participants reported 12 episodes of level 1 symptomatic hypoglycemia: 2 at session 2, 8 at session 3, and 2 at session 4. These were defined as “trembling, sweaty, pounding heart, unusual fatigue, pale skin, anxiety, irritability, with BG usually in the 60s, but it could be slightly higher or lower.” During the blinded CGM period, using the criterion that hypoglycemia events are defined as BG of 70 mg/dL or less [7], GEM and RC did not significantly differ regarding the pre and post change in the number of hypoglycemic events recorded.

3. Discussion

This study replicates our previous report [3] that found, relative to RC, that GEM led to a significant reduction in HbA1c in adults with T2D. The present study extends those findings by demonstrating that when CGM was
used instead of systematic BG monitoring, GEM\textsuperscript{CGM} reduced HbA\textsubscript{1c} by a mean of 1.3% instead of the previous 1.0%, and did so with 20% fewer contacts (4 vs 5 training sessions) in a more diverse participant sample (longer diabetes duration, taking more varied diabetes medications). Further, the present study demonstrated that GEM\textsuperscript{CGM} reduced HbA\textsubscript{1c} and MES more than RC (1.1% and 0.83, respectively), for a TTE difference of 1.94% HbA\textsubscript{1c} equivalent between the 2 groups (see Fig. 2).

Compared to RC, GEM\textsuperscript{CGM} increased physical activity and decreased hyperglycemic excursions (AUC). However, these were not significantly different from RC. This was in part because the Dexcom G4 platinum captured only a maximum of 6.5 days of CGM data, the BG sampled in the HbA1c and blinded CGM measures did not overlap temporally (CGM followed the A1c), and the small sample size and large CGM SDs (see Table 3) restricted statistical power. However, changes in these parameters did significantly correlate with improvement in HbA\textsubscript{1c}, as did physical activity in a previous study [15]. Similarly to the previous study, GEM\textsuperscript{CGM} was associated with multiple psychological benefits compared to RC, including improvements in quality of life, greater sense of empowerment, and reduction in diabetes distress.

These benefits were achieved without worsening lipids or increasing hypoglycemia. It is interesting to note that no GEM\textsuperscript{CGM} participants experienced level 2 hypoglycemia, whereas 2 RC participants, either having gone on insulin or glipizide, experienced 3 level 2 hypoglycemia events per patient during follow-up. This is reflected by an area within the curve under 70 mg/dL. RC showed a pre and post increase of 639 ± 1204, whereas GEM\textsuperscript{CGM} demonstrated an increase of 7 ± 22. These changes were not significantly different because of RC’s large variance.

Sample size is a significant limitation of the present study, potentially limiting the external validity of these findings and precluding investigation of individual differences. However, given replication of a previous study [3] with a different sample, any threat to external validity in the present study is diminished. The sample size was too small for the 2 groups to be matched on all variables. Although not significantly different, the RC group contained more female

### Table 2. Preassessment to postassessment change in study variables and statistical significance

| Variable                                      | Routine care, mean ± SD | GEM\textsuperscript{CGM}, mean ± SD | F    | P    |
|------------------------------------------------|-------------------------|-------------------------------------|------|------|
| **Primary outcome variables**                  |                         |                                     |      |      |
| HbA\textsubscript{1c} (%)                     | –0.19 ± 1.81            | –1.30 ± 0.89                        | 5.57 | .03  |
| Medication effect score                        | 0.81 ± 1.17             | –0.02 ± 0.44                        | 7.85 | .009 |
| Total treatment effect                         | 0.62 ± 2.03             | –1.32 ± 1.09                        | 11.29| .000 |
| **Mechanisms**                                 |                         |                                     |      |      |
| Diabetes knowledge                             | –0.6 ± 2.4              | 3.7 ± 2.6                           | 13.41| .001 |
| Net carbohydrates (ASA24)                     | 6.4 ± 112.5             | –72.6 ± 75.8                        | 8.17 | .009 |
| Average CDC active minutes (Fitbit)           | –6.7 ± 36.0             | 4.5 ± 39.4                          | 1.29 | .27  |
| Activity calories (Fitbit)                    | –22.7 ± 454.1           | 84.7 ± 454.3                        | 0.60 | .45  |
| PHQ9 Depression symptoms                      | –1.4 ± 6.7              | –2.3 ± 5.1                          | 3.34 | .08  |
| **Secondary variables**                        |                         |                                     |      |      |
| WHO-QOL (Physiological)                       | 0.1 ± 1.7               | 0.1 ± 1.4                           | 1.35 | .26  |
| WHO-QOL (Psychological)                       | –0.8 ± 1.0              | 0.4 ± 1.6                           | 6.99 | .01  |
| Glucose Monitor Satisfaction Survey           | 0.1 ± 0.6               | 0.5 ± 0.6                           | 7.19 | .01  |
| Diabetes empowerment                           | 0.9 ± 3.4               | 3.4 ± 4.8                           | 4.36 | .05  |
| Diabetes Distress Scale (emotional)           | 0.2 ± 1.1               | –0.5 ± 1.1                          | 6.64 | .02  |
| Diabetes Distress Scale (regimen)             | –0.1 ± 0.7              | –0.9 ± 1.1                          | 7.20 | .01  |
| **Side effects**                               |                         |                                     |      |      |
| Calories (ASA24)                               | –12 ± 957               | –190 ± 719                          | 3.68 | .07  |
| Total fat (ASA24)                              | 3.2 ± 37.7              | 6.6 ± 37.4                          | 2.92 | .10  |
| Saturated fat (ASA24)                          | –2.6 ± 13.4             | 2.6 ± 14.2                          | 0.03 | .87  |
| Protein (ASA24)                                | –2.3 ± 56.2             | 10.4 ± 34.5                         | 0.20 | .66  |
| LDL                                            | –8.9 ± 31.9             | 1.1 ± 18.2                          | 0.16 | .70  |
| HDL                                            | –0.9 ± 7.0              | 2.8 ± 6.2                           | 1.22 | .28  |
| Triglycerides                                  | 15.6 ± 98.4             | –27.6 ± 62.6                        | 1.48 | .24  |
| Total cholesterol                              | –5.3 ± 35.6             | –3.3 ± 22.9                         | 0.01 | .93  |
| Avg daily hypo AWC < 70 mg/dL, CGM             | 639 ± 1204              | 7 ± 22                              | 1.07 | .32  |

Abbreviations: ASA24, automated self-administered 24-hour dietary recall; AWC, area within the curve; CDC, Centers for Disease Control; CGM, continuous glucose monitoring; GEM\textsuperscript{CGM}, glycemic excursion minimization plus real-time continuous glucose monitoring; HbA\textsubscript{1c}, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PHQ9, Patient Health Questionnaire-9; WHO-QOL, World Health Organization Quality of Life.
Table 3. Blinded continuous glucose monitoring (CGM) results. Percentage of time CGM was in different glucose ranges and CGM area under the curve (AUC) when blood glucose (BG) was greater than 180 mg/dL. No significant group differences were found.

| BG range, mg/dL | Routine care, pre | Routine care, post | GEM_{CGM}, pre | GEM_{CGM}, post |
|-----------------|------------------|--------------------|----------------|----------------|
| < 54            | 0%               | 1%                 | 0%             | 0%             |
| 54-69           | 0%               | 1%                 | 0%             | 0%             |
| 70-180          | 42%              | 43%                | 44%            | 50%            |
| 181-250         | 31%              | 29%                | 32%            | 27%            |
| > 250           | 27%              | 26%                | 24%            | 23%            |
| Average daily excursion AUC (> 180) | 32 790 ± 32 775 | 35 942 ± 34 111 | 35 345 ± 46 259 | 33 336 ± 53 315 |

Abbreviation: GEM_{CGM}, glycemic excursion minimization plus real-time continuous glucose monitoring.

and fewer white participants. Furthermore, the sustainability of these findings is not certain given that the present study employed only a 3-month follow-up. Additionally, given that we recruited individuals interested in using CGM, these findings cannot be extrapolated to the broader T2D community, which includes people uninterested in CGM for a variety of reasons as noted previously. Finally, as in our previous study, which did not separate the effects of BG monitoring from the GEM didactic information, the present study does not separate any additive benefits of CGM from GEM didactics. This will be addressed in a future study.

These findings indicate that GEM_{CGM} is a viable option for adults with T2D interested in CGM, and gives diabetes clinicians an additional tool to aid consumers with T2D. It will be up to future studies to determine whether GEM_{CGM} is equivalent or superior to conventional weight loss therapy, which intervention is more sustainable, and which option best matches which patient characteristics.

Acknowledgments

We wish to thank our lay advisory board and our professional advisory board (Dr Larry Fisher, Dr Mary DeGroot, and Dr Barbara Anderson) for their input. We also thank Victoria Ngo and Simone Buckman for assistance in conducting the study.

Financial Support: This work was supported by Dexcom, Inc (Grant IIS-2017-047 for equipment and financial support) and the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (Grant DK108957). The funding sources were not involved in the design or conduct of the study, nor in the preparation of this manuscript.

Clinical Trial Information: Clinicaltrials.gov registration no. NCT03207893 (registered July 5, 2017).

Additional Information

Correspondence: Daniel J. Cox, PhD, Center for Behavioral Medicine Research, University of Virginia Health System, P.O. Box 800223, Charlottesville, VA 22908, USA. E-mail: djc44@virginia.edu.

Disclosure Summary: The authors have nothing to disclose.

Data Availability: The data sets generated during and/or analyzed during the present study are not publicly available but are available from the corresponding author on reasonable request.

References

1. Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

2. American Diabetes Association (ADA). Standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1): S1-S212.

3. Cox DJ, Taylor AG, Singh H, et al. Glycemic load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment of type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;111:28-35.

4. Ceriello A, Davidson J, Hanefeld M, et al; International Prandial Glucose Regulation Study Group. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis. 2006;16(7):453-456.

5. Polonsky WH, Fisher L. Self-monitoring of blood glucose in noninsulin-using type 2 diabetic patients: right answer, but wrong question: self-monitoring of blood glucose can be clinically valuable for noninsulin users. Diabetes Care. 2013;36(1):179-182.

6. Cox DJ, Basu R, McCall A. Continuous glucose monitoring functions as a negative feedback loop for individuals with type 2 diabetes. Ann Diabetes Metab Disorders Control. 2018;1(3):121.

7. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155-157.

8. Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life. Diabetes Technol Ther. 2015;17(9):657-663.

9. World Health Organization. The world health organization quality of life (WHOQOL)-BREF. No. WHO/HIS/HSI Rev. 2012.02. World Health Organization, 2004.
10. Anderson RM, Funnell MM, Fitzgerald JT, Marrero DG. The Diabetes Empowerment Scale: a measure of psychosocial self-efficacy. *Diabetes Care.* 2000;23(6):739-743.

11. Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes; development of the Diabetes Distress Scale. *Diabetes Care.* 2005;28(3):626-631.

12. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001;16(9):606-613.

13. Alexopoulos AS, Yancy WS, Edelman D, et al. Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. [Published online ahead of print October 25, 2019.] *Chronic Illn.* Doi:10.1177/1742395319884096

14. Subar AF, Kirkpatrick SI, Mittl B, et al. The automated self-administered 24-hour dietary recall (ASA24): a resource for researchers, clinicians, and educators from the National Cancer Institute. *J Acad Nutr Diet.* 2012;112(8):1134-1137.

15. Garcia JM, Cox D, Rice DJ. Association of physiological and psychological health outcomes with physical activity and sedentary behavior in adults with type 2 diabetes. *BMJ Open Diabetes Res Care.* 2017;5(1):e000306.